Beyond Air Announces CFO Transition

Air Announces CFO Transition

CITY, N.Y., August 20, 2021 (GLOBE NEWSWIRE) - Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical

company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious

lung infections and pulmonary hypertension, and gaseous NO (gNO) for the treatment of solid tumors, today announced the appointment of

Douglas Larson as Chief Financial Officer, succeeding Douglas Beck effective September 1, 2021. Mr. Beck will remain a consultant to

the Company and is expected to work closely with Mr. Larson and the Beyond Air leadership team to ensure a seamless transition of CFO

Larson joins Beyond Air with over 20 years of international and operational financial leadership experience. Recently he served as Vice

President, Finance and Head of Global Controlling at DBV Technologies, Inc. (NASDAQ: DBVT), a global clinical stage biopharmaceutical

company headquartered in France, from 2017 to 2020. Prior to DBV, Mr. Larson served as the Chief Financial Officer of The Scotts Miracle-Gro

Company's International division, based in Lyon, France from 2001 to 2015. Mr. Larson has a deep knowledge of performance management,

supply chain finance, forecasting and business modeling, and defining and executing strategic and financial goals for companies in various

stages of development across a diverse geographic footprint.

behalf of the Board of Directors and the entire company, I want to thank Mr. Beck for his commitment to Beyond Air and continued support.

Since joining in 2018, Mr. Beck has been instrumental to our success, leading with a forward-thinking mindset and establishing the financial

foundation for our future development and growth. He leaves the Company in a strong cash position, and I personally want to thank him

for his contributions and wish him the best in his future endeavors," commented Steve Lisi, Chairman and Chief Executive Officer

of Beyond Air. "This transition comes at a time of tremendous momentum for Beyond Air, and I am excited to welcome Douglas Larson

to effectively guide the Company through our transition to a commercial stage entity."

connection with the appointment of Mr. Larson, the Company granted Mr. Larson an inducement stock option award (the "Inducement

Option") as an inducement material to Mr. Larson's entering into employment with the Company in accordance with Nasdaq Stock

Market Listing Rule 5635(c)(4). The Inducement Option is being granted effective as of September 1, 2021 and is exercisable for the purchase

of 75,000 shares of the Company's common stock, at an exercise price equal to the last reported sale price on Nasdaq on September

1, 2021. The Inducement Option grant was approved by the independent compensation committee of the Board in accordance with Nasdaq Stock

Market Listing Rule 5635(c)(4). The Inducement Option has a ten-year term and will vest over a four-year period, with 25% of the shares

underlying the stock option award vesting on the first anniversary of the date of grant and annually thereafter in three equal installments,

subject to Mr. Larson's continued service with the Company through the applicable vesting dates. The Inducement Option is subject

to the terms and conditions of the Company's 2013 Equity Incentive Plan.

Air, Inc. is a clinical-stage medical device and biopharmaceutical company developing a revolutionary NO Generator and Delivery System,

LungFit , that uses NO generated from ambient air to deliver precise amounts of NO to the lungs for the potential treatment

of a variety of pulmonary diseases. The LungFit can generate up to 400 ppm of NO, for delivery either continuously or

for a fixed amount of time and has the ability to either titrate dose on demand or maintain a constant dose. The Company is currently

applying its therapeutic expertise to develop treatments for pulmonary hypertension in various settings, in addition to treatments for

respiratory tract infections that are not effectively addressed with current standards of care. Beyond Air is currently advancing its

revolutionary LungFit for clinical trials for the treatment of severe lung infections such as acute viral pneumonia (including

COVID-19) and nontuberculous mycobacteria (NTM). Additionally, Beyond Air is using ultra-high concentrations of NO with a proprietary

delivery system to target certain solid tumors in the pre-clinical setting. For more information, visit www.beyondair.net.

statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future

operations, and other statements containing the words "anticipates,"

"expects," "intends," "impacts," "plans," "projects," "believes,"

"estimates," "likely," "goal," "assumes," "targets" and similar expressions

and/or the use of future tense or conditional constructions (such as "will," "may," "could," "should"

and the like) constitute forward-looking statements within the meaning of The Private Securities

Litigation Reform Act of 1995. These statements do not relate strictly to historical or current matters. Rather, forward-looking

statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking

statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could

cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. These forward-looking

statements are only predictions and reflect our views as of the date they are made with respect to future events and financial performance.

Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking

statements, including risks related to: our approach to discover and develop novel drugs, which is unproven and may never lead to efficacious

or marketable products; our ability to fund and the results of further pre-clinical and clinical trials; obtaining, maintaining and protecting

intellectual property utilized by our products; our ability to enforce our patents against infringers and to defend our patent portfolio

against challenges from third parties; our ability to obtain additional funding to support our business activities; our dependence on

third parties for development, manufacture, marketing, sales, and distribution of products; the successful development of our product

candidates, all of which are in early stages of development; obtaining regulatory approval for products; competition from others using

technology similar to ours and others developing products for similar uses; our dependence on collaborators; our short operating history

and other risks identified and described in more detail in the "Risk Factors" section of the Company's most recent

Annual Report on Form 10-K and other filings with the SEC, all of which are available on our website. We undertake no obligation to update,

and we do not have a policy of updating or revising, these forward-looking statements, except as required by applicable law.

Yonkoski, Head of Investor Relations